Resource Logo
NLM AIDSLINE

LARGE CELL LYMPHOMAS (LCL) EXPRESSING KI-1 (CD30) POSITIVITY: CLINICAL FEATURES OF 15 PATIENTS (MEETING ABSTRACT)




 

Proc Annu Meet Am Soc Clin Oncol; 11:A1115 1992. Unique Identifier :

From 7/87 to 6/91, 15 patients (pts), 12 males and 3 females, with Ki-1-positive LCL were identified. Median age at presentation was 41 yr (21-75). Ann Arbor Stages were I (3), II (2), III (4) or IV (6); 11 pts had B symptoms. Eight pts had bulky (greater than 10 cm) disease. Two pts had serum LDH greater than twice normal. Only 3 pts had disease limited to nodal sites. Most common sites of extranodal disease were soft tissue (6) and skin (3). None were HIV or HTLV-1 antibody positive. Immunophenotyping revealed 4 T-cell, 3 B-cell and 8 undefined LCL: all expressed Ki-1 (Ber-H2). Pts were treated with resection alone if LCL was limited to the skin (2), radiotherapy (RT; 1), multiagent chemotherapy, VACOP-B (9) if less than 67 yr or protocols for elderly if older (2), or combination of chemo-RT (1). Complete response was obtained in 11 pts (73%), of which 2 recurred (13%). One then had high-dose chemotherapy and autologous BMT, remaining in remission since. One died without evidence of LCL. Two achieved partial remission, 1 rendered disease-free after additional RT. Four pts (27%) have died for an overall 4-yr survival of 73% with a median follow-up of 19 mo. Two pts with small localized skin presentation have remained disease-free after resection only. In our experience, Ki-1 + LCL more frequently presents with bulky disease and extranodal extension, but has a prognosis at least as good as other large cell lymphomas similarly treated at our institution.

Aged Antigens, CD/*ANALYSIS Antigens, Neoplasm/*ANALYSIS Bleomycin/THERAPEUTIC USE Bone Marrow Transplantation Combined Modality Therapy Cyclophosphamide/THERAPEUTIC USE Doxorubicin/THERAPEUTIC USE Etoposide/THERAPEUTIC USE Female Human Lymphatic Metastasis Lymphoma, Large-Cell/DRUG THERAPY/*IMMUNOLOGY/RADIOTHERAPY/ SURGERY Male Middle Age Prednisone/THERAPEUTIC USE Vincristine/THERAPEUTIC USE ABSTRACT



 




Information in this article was accurate in October 30, 1992. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.